We’ve expanded our Lipoderm family of permeation-enhancing bases and offer helpful tips, including which Lipoderm base works best for specific APIs, when compounding preparations for your patients.

Read more about how Canada and the U.S. regulators approach drug shortages, including duplicating approved drugs and the impacts of last winter’s drug shortages.

North America’s two largest countries, Canada and the U.S., have very different approaches to drug shortages. Read Part 1 of our two-part series to learn more about the distinctions between Health Canada and FDA regulations.

As we wind down National Arthritis Awareness Month, learn how compounders may help patients with the most common type of arthritis using compounded preparations and nutritional supplements.

Polycystic ovary syndrome (PCOS) is the most prevalent hormonal disorder affecting women of reproductive age across the globe and the CDC estimates PCOS may be one of the most common causes of infertility. Learn how to help patients with PCOS.

Genitourinary syndrome of menopause (GSM), also known as vulvovaginal atrophy, is common among menopausal women. Learn more about GSM, relevant hormones and the importance of choosing the right base for compounding preparations.

Scientists detected evidence of DNA methylation abnormalities in patients with autism spectrum disorder (ASD). Learn how compounders may potentially help ASD patients with methylcobalamin preparations.

Learn why methylene blue, synthesized in 1876 as a dye for the textile industry, has rekindled interest for therapeutic use in diseases.

Read why Kayla Valigura, PharmD candidate and 2022 PCCA Institute Scholarship award winner, wants your help in acting on something near and dear to her heart.

PCCA's Matt Martin and Melissa Merrell Rhoads provide guidance and examples to help you determine API calculations in your compounding pharmacy.